banner

Posts tagged as: Aeterna Zentaris news back to homepage

Aeterna Zentaris Stock Chart Analysis Video Aeterna Zentaris Stock Chart Analysis Video(0)

Three straight days of closing ahead has the AEterna Zentaris chart on watch for continued upward pressure. Shares rose 8.5 percent on Tuesday to close near the high of the day on increased volume, which is a bullish sign as the stock nears resistance. Shares traded as low as $1.75 last week, but have recovered to close on Tuesday at $2.16 on Read More

Aeterna Zentaris Continues Pursuing Drug Development for Multiple Myeloma(0)

The path to bring a new cancer drug to market can certainly be a long and bumpy road full of twists and turns.  It was about one month ago that the news hit of Aeterna Zentaris (TSX: AEZ)(NASDAQ: AEZS) and Keryx Biopharmaceuticals (NASDAQ: KERX) terminating their license agreement with respect to perifosine, an Akt inhibiting oral anticancer compound; giving back full North American rights to Aeterna. Read More



Stay Informed

Receive the OTCS Newsletter *




*

* required

Dana-Farber to Host Cellceutix Trials

Cellceutix Corporation (CTIX)
Cellceutix Corporation has filed its Investigational New Drug application with the FDA. Dana-Farber and Beth Israel Deaconess Medical Center will be hosting the clinical trials for Kevetrin, Cellceutix's novel cancer drug. Read more news and get a stock quote.

Diabetes Rate Growing Exponentially

According to the International Diabetes Federation, more than 500 million people will be diagnosed with diabetes in the next two decades, a more than 50 percent increase from today. Technologies are available presently to help manage the frequency, complications and costs associated with diabetes. Read the complete article to learn more.

Contacts and information

Have an opinion or news that you want to share?

Social networks

Most popular categories

Disclaimer/Disclosure
© 2011 Viper Enterprises, LLC. All rights reserved.